Should I buy or sell Compugen stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CGEN shares. View CGEN analyst ratings or view top-rated stocks .

What is Compugen's stock price target for 2024?

5 brokerages have issued 1 year price objectives for Compugen's shares. Their CGEN share price targets range from $4.00 to $13.00. On average, they anticipate the company's stock price to reach $8.33 in the next year. This suggests a possible upside of 954.9% from the stock's current price. View analysts price targets for CGEN or view top-rated stocks among Wall Street analysts .

How have CGEN shares performed in 2023?

Compugen's stock was trading at $0.7157 at the beginning of 2023. Since then, CGEN stock has increased by 10.4% and is now trading at $0.79. View the best growth stocks for 2023 here .

Are investors shorting Compugen?

Compugen saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 1,350,000 shares, a decline of 10.6% from the October 31st total of 1,510,000 shares. Based on an average daily trading volume, of 174,600 shares, the short-interest ratio is currently 7.7 days. Currently, 1.6% of the shares of the company are short sold. View Compugen's Short Interest .

When is Compugen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our CGEN earnings forecast .

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) released its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02.

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?

2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com . Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , QUALCOMM (QCOM) , AbbVie (ABBV) , Inovio Pharmaceuticals (INO) , Netflix (NFLX) , Gilead Sciences (GILD) and Pfizer (PFE) .

Who are Compugen's major shareholders?

Compugen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (2.23%), Silverarc Capital Management LLC (0.40%), UBS Group AG (0.32%), Kingsview Wealth Management LLC (0.10%), Tocqueville Asset Management L.P. (0.09%) and Oppenheimer & Co. Inc. (0.04%).

How do I buy shares of Compugen?

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Compugen Stock Price, News & Analysis (NASDAQ:CGEN)

$0.79

+0.01 (+1.28%)

(As of 12/5/2023 ET)

Compare

Today's Range: $0.77
▼
$0.83
50-Day Range: $0.53
▼
$0.96
52-Week Range: $0.53
▼
$1.49

Volume: 382,278 shs
Average Volume: 363,156 shs
Market Capitalization: $68.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.33

Compugen MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 954.9% Upside
$8.33 Price Target
Short Interest: Healthy
1.62% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.31) to ($0.44) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

636th out of 948 stocks

Biotechnology Industry

25th out of 46 stocks

3.3

Analyst's Opinion

Consensus Rating
Compugen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $8.33, Compugen has a forecasted upside of 954.9% from its current price of $0.79.
Amount of Analyst Coverage
Compugen has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.62% of the float of Compugen has been sold short.
Short Interest Ratio / Days to Cover
Compugen has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in Compugen has recently decreased by 10.60%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Compugen does not currently pay a dividend.
Dividend Growth
Compugen does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CGEN.

2.2

News and Social Media Coverage

News Sentiment
Compugen has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Compugen this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Compugen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Compugen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.50% of the stock of Compugen is held by insiders.
Percentage Held by Institutions
Only 13.25% of the stock of Compugen is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Compugen are expected to decrease in the coming year, from ($0.31) to ($0.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Compugen is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Compugen is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Compugen has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Compugen Stock (NASDAQ:CGEN)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

CGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CGEN Stock News Headlines

December 5, 2023 | finance.yahoo.com

Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?

November 9, 2023 | finance.yahoo.com

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

November 8, 2023 | finance.yahoo.com

Compugen Ltd. (NASDAQ:CGEN) Q3 2023 Earnings Call Transcript

November 8, 2023 | msn.com

Compugen GAAP EPS of -$0.11 misses by $0.02

November 7, 2023 | sfgate.com

Compugen: Q3 Earnings Snapshot

November 6, 2023 | msn.com

Compugen Q3 2023 Earnings Preview

November 6, 2023 | finance.yahoo.com

Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

November 3, 2023 | msn.com

Compugen receives non-compliance notice from Nasdaq

November 3, 2023 | finance.yahoo.com

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

October 31, 2023 | finance.yahoo.com

Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer

October 24, 2023 | finance.yahoo.com

Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023

October 3, 2023 | finance.yahoo.com

Compugen to Present at Single Cell Genomics 2023 Meeting

October 2, 2023 | markets.businessinsider.com

Compugen Gets Patent In Japan For Combination Of Anti-PVRIG, TIGIT, PD-1 Antibody To Treat Cancer

October 2, 2023 | finance.yahoo.com

Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer

September 27, 2023 | finance.yahoo.com

Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023

August 31, 2023 | finance.yahoo.com

Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 23, 2023 | msn.com

Roche sends anti-TIGIT developers higher after cancer drug data (update)

August 10, 2023 | finance.yahoo.com

Compugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call Transcript

August 8, 2023 | nl.investing.com

Compugen winst hoger dan voorspeld, omzet volgens verwachting

August 8, 2023 | markets.businessinsider.com

5 Analysts Have This to Say About Compugen

August 7, 2023 | finance.yahoo.com

Compugen Reports Second Quarter 2023 Results

July 24, 2023 | finance.yahoo.com

Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023

July 17, 2023 | finance.yahoo.com

Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party

July 15, 2023 | finance.yahoo.com

CGEN - Compugen Ltd.

July 6, 2023 | msn.com

Compugen (CGEN) Price Target Increased by 17.39% to 6.89

See More Headlines

Receive CGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CGEN
CUSIP: N/A
CIK: 1119774
Web: www.cgen.com
Phone: (723) 765-8585
Fax: 972-3765-8555
Employees: 69
Year Founded: 1993

Price Target and Rating

Average Stock Price Target: $8.33
High Stock Price Target: $13.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +954.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,690,000.00
Net Margins: N/A
Pretax Margin: -420.49%
Return on Equity: -48.16%
Return on Assets: -39.06%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.81
Quick Ratio: 6.43

Sales & Book Value

Annual Sales: $7.50 million
Price / Sales: 9.12
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.90 per share
Price / Book: 0.88

Miscellaneous

Outstanding Shares: 86,625,000
Free Float: 78,396,000
Market Cap: $68.43 million
Optionable: Optionable
Beta: 2.52

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Anat Cohen-Dayag Ph.D. (Age 56)
CEO, President & Director
Comp: $796.52k
Dr. Zurit Levine Ph.D. (Age 55)
Senior Vice President of Technology Innovation
Comp: $345.7k
Dr. Henry Adewoye M.D. (Age 58)
Senior VP & Chief Medical Officer
Comp: $605.29k
Dr. Pierre Ferre Ph.D. (Age 46)
Vice President of Preclinical Development
Comp: $415.1k
Mr. Alberto Sessa (Age 61)
Chief Financial Officer
Dr. Eran Ophir Ph.D. (Age 45)
Chief Scientific Officer
Ms. Yvonne Naughton
Head of Investor Relations & Corporate Communications
Mr. Eran Ben Dor
General Counsel & Corporate Secretary
Ms. Dorit Amitay (Age 55)
Vice President of Human Resources
Dr. Yaron Turpaz M.B.A. (Age 52)
Ph.D., Senior VP & Senior Advisor of Data and Informatics Solutions

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Compugen stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CGEN shares.
View CGEN analyst ratings or view top-rated stocks.
What is Compugen's stock price target for 2024?: 5 brokerages have issued 1 year price objectives for Compugen's shares. Their CGEN share price targets range from $4.00 to $13.00. On average, they anticipate the company's stock price to reach $8.33 in the next year. This suggests a possible upside of 954.9% from the stock's current price.
View analysts price targets for CGEN or view top-rated stocks among Wall Street analysts.
How have CGEN shares performed in 2023?: Compugen's stock was trading at $0.7157 at the beginning of 2023. Since then, CGEN stock has increased by 10.4% and is now trading at $0.79.
View the best growth stocks for 2023 here.
Are investors shorting Compugen?: Compugen saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 1,350,000 shares, a decline of 10.6% from the October 31st total of 1,510,000 shares. Based on an average daily trading volume, of 174,600 shares, the short-interest ratio is currently 7.7 days. Currently, 1.6% of the shares of the company are short sold.
View Compugen's Short Interest.
When is Compugen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our CGEN earnings forecast.
How were Compugen's earnings last quarter?: Compugen Ltd. (NASDAQ:CGEN) released its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02.

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?: 2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Compugen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).
Who are Compugen's major shareholders?: Compugen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (2.23%), Silverarc Capital Management LLC (0.40%), UBS Group AG (0.32%), Kingsview Wealth Management LLC (0.10%), Tocqueville Asset Management L.P. (0.09%) and Oppenheimer & Co. Inc. (0.04%).
How do I buy shares of Compugen?: Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CGEN) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial